FIELD: pharmaceutical industry.
SUBSTANCE: present invention relates to the use of an antibiotic with specific therapeutic indications in an effective amount in association with a bifidobacteria strain. Using an antibiotic with specific therapeutic indications in an effective amount in association with a bifidobacteria strain, where said bifidobacteria strain exhibits resistance to an antibiotic not transmitted to other species, and is also used for the same therapeutic indications as said antibiotic for treating diseases, selected from: acute and chronic intestinal infections caused by gram-positive and gram-negative bacteria; diarrheal syndromes; diarrhea caused by intestinal microflora imbalance, selected from summer diarrhea, travelers' diarrhea and enterocolitis; for pre- and postoperative prevention of infectious complications in gastrointestinal surgery; gastrointestinal disorders, such as irritable bowel syndrome (IBS), constipation and changes of intestinal microflora; chronic inflammatory intestinal diseases (CIID) (also known as inflammatory bowel diseases (IBD)), which include Crohn's disease and ulcerative rectocolitis; and Helicobacter pylori infections, wherein said antibiotic is selected from a group consisting of rifamycin and rifaximin, where said bifidobacteria strain is Bifidobacterium longum W11, access number LMG P-21586 deposited in the Belgian coordinated collection of microorganisms BCCM LMG, where said strain has concentration of 1×109 to 1×1012 live cells per gram of said strain, where bacteria are coated with a protein matrix, wherein said antibiotic is administered simultaneously with bacterial strain Bifidobacterium longum W11 LMG P-21586 and wherein said antibiotic and said bacterial strain are administered individually or in one composition.
EFFECT: what is presented is the use of antibiotics with specific therapeutic activities combined with simultaneous application of lactobacilli and/or bifidobacteria with persistent resistance to antibiotics, having the same therapeutic value.
6 cl, 2 tbl
Authors
Dates
2020-12-04—Published
2016-04-29—Filed